Enlightened by the modification route from Camptothecin (CPT) to Topotecan and based on classical drug design theory, a series of Mannich derivatives of lamellarin D were designed and synthesized in 26–27 steps starting from vanillin and isovanilin. All synthesized compounds were then biologically evaluated for their in vitro anti-cancer activities and Topo I inhibitory activities. The results showed
从
喜树碱(C
PT)到托泊替康的修饰途径的启发,并基于经典药物设计理论,从
香草醛和异缬
氨酸开始,以26–27个步骤设计并合成了一系列lamellarin D的曼尼希衍
生物。然后对所有合成的化合物进行体外抗癌活性和Topo I抑制活性的
生物学评估。结果表明,大多数目标化合物对Topo I的抑制活性与薄层蛋白D相当。化合物SL-9对Topo I的抑制活性比薄层蛋白D更好。化合物S
L-2,SL-3,SL-4,SL-5和SL-11 与lamellarin D相比,对HT-29细胞具有更好的抗增殖活性。